State Street Corp Exelixis, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, State Street Corp holds 11,443,668 shares of EXEL stock, worth $385 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

11,443,668

Previous 12,601,656 9.19%

Holding current value

$385 Million

Previous $283 Million 4.87%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $25.4 Million - $32 Million	-1,157,988 Reduced 9.19%	11,443,668 $297 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $9.76 Million - $11.4 Million	-479,751 Reduced 3.67%	12,601,656 $283 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $980,040 - $1.16 Million	48,589 Added 0.37%	13,081,407 $310 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $12.6 Million - $15.7 Million	652,074 Added 5.27%	13,032,818 $313 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $9.72 Million - $11.6 Million	-510,543 Reduced 3.96%	12,380,744 $271 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $1.22 Million - $1.37 Million	-66,908 Reduced 0.52%	12,891,287 $246 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $13.3 Million - $15.9 Million	-817,773 Reduced 5.94%	12,958,195 $252 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $11.3 Million - $13.1 Million	756,068 Added 5.81%	13,775,968 $221 Million
Q3 2022 Nov 15, 2022	BUY	$15.68 - $22.27 $6.64 Million - $9.43 Million	423,520 Added 3.36%	13,019,900 $204 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $21.3 Million - $28.2 Million	1,219,174 Added 10.72%	12,596,380 $262 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $1.33 Million - $1.77 Million	78,064 Added 0.69%	11,377,206 $258 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $11 Million - $15.2 Million	692,622 Added 6.53%	11,299,142 $207 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $13.6 Million - $17.7 Million	834,939 Added 8.54%	10,606,520 $224 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $9.53 Million - $13.6 Million	531,118 Added 5.75%	9,771,581 $178 Million
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $20.3 Million - $24.9 Million	-986,656 Reduced 9.65%	9,240,463 $209 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $19.7 Million - $26.6 Million	1,072,533 Added 11.72%	10,227,119 $205 Million
Q3 2020 Nov 10, 2020	SELL	$20.67 - $26.94 $10.7 Million - $13.9 Million	-517,567 Reduced 5.35%	9,154,586 $224 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $27.7 Million - $46.1 Million	-1,682,822 Reduced 14.82%	9,672,153 $230 Million
Q1 2020 May 11, 2020	BUY	$14.46 - $21.8 $164 Million - $248 Million	11,354,975 New	11,354,975 $196 Million

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Exelixis, Inc. Transaction History